|
2025 Journal Article ALLG APML5: Bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APLIland, Harry J, Reynolds, John, Boddy, Alan, Schultz, Hayley B, Khoo, Liane, Fleming, Shaun A, Lane, Steven W, Weber, Nicholas, Gasiorowski, Robin, Armytage, Tasman, Harrup, Rosemary Anne, Watson, Anne-Marie, Tan, Peter, Filshie, Robin, Kwok, Fiona, Stevenson, William S., Yuen, Sam L.S., Ng, Ashley Peng Chee, Rowley, Leesa, Marlton, Paula and Wei, Andrew H (2025). ALLG APML5: Bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL. Blood Advances, 9 (6), 1476-1484. doi: 10.1182/bloodadvances.2024015397 |
|
2024 Conference Publication Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1c-Flt3ITD Acute Myeloid LeukemiaTavakoli, Paniz, Bywater, Megan, Straube, Jasmin, Ling, Victoria, Cooper, Emily, Haldar, Rohit, Janardhanan, Yashaswini, Cooper, Leanne, Bruedigam, Claudia, Grove, Carolyn S. and Lane, Steven W. (2024). Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1c-Flt3ITD Acute Myeloid Leukemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-201250 |
|
2024 Conference Publication CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF HypersensitivityLim, Kelly, Kutyna, Monika, Kan, Winnie, Lopez, Angel F., Brown, Anna, Yong, Agnes S. M., Lane, Steven W., Fong, Chun Yew, Hughes, Timothy P., Yeung, David T., Ross, David M., Hiwase, Devendra and Thomas, Daniel (2024). CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-202682 |
|
2024 Conference Publication Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell CompartmentsStraube, Jasmin, Grabek, Julian, Cooper, Leanne, Haldar, Rohit, McNamara, Caroline, Ross, David M., Perkins, Andrew, Bywater, Megan and Lane, Steven W. (2024). Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-199841 |
|
2024 Conference Publication Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and AzacitidineHiwase, Devendra, Ross, David M., Yeung, David T., Yong, Agnes S. M., Lane, Steven W., Brown, Anna, Fong, Chun Yew, Hughes, Timothy P., Reynolds, John and Thomas, Daniel (2024). Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-202867 |
|
2024 Conference Publication High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with AzacitidineKamel, Maha M., Robinson, Nirmal, Kutyna, Monika, Lim, Kelly, Thompson-Peach, Chloe, Lane, Steven W., Yeung, David T., Yong, Agnes S. M., Ross, David M., Hiwase, Devendra and Thomas, Daniel (2024). High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204177 |
|
2024 Conference Publication Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is RareYeung, David T., Shanmuganathan, Naranie, Yong, Agnes S. M., Shortt, Jake, Chee, Lynette C.Y., Vialla, Nicholas, Cunningham, Ilona, Ross, David M., D'Souza, Alwyn, Wright, Matthew P.F., Harrup, Rosemary, Forsyth, Cecily, Filshie, Robin, Lane, Steven W., Browett, Peter J., Grove, Carolyn S., Walia, Mannu, Branford, Susan, Reynolds, John, Grigg, Andrew P. and Hughes, Timothy P. (2024). Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-201218 |
|
2024 Conference Publication Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid LeukemiaBruedigam, Claudia, Dulatre, Eunice Anne, Lee, Carol, Porter, Amy H., Lim, Elisa L.S.P., Shi, Alexander Z., Hodson, Mark P., Heidel, Florian H. and Lane, Steven W. (2024). Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-206473 |
|
2024 Journal Article CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targetingLim, Kelly, Kan, Winnie L., Nair, Pramod C., Kutyna, Monika, Lopez, Angel F., Hercus, Timothy, Ross, David M., Lane, Steven, Fong, Chun Yew, Brown, Anna, Yong, Agnes, Yeung, David, Hughes, Timothy, Hiwase, Devendra and Thomas, Daniel (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19 (9 September) e0310641, 1-19. doi: 10.1371/journal.pone.0310641 |
|
2024 Journal Article Identifying disease-modifying potential in myelofibrosis clinical trialsRoss, David M, Lane, Steven W and Harrison, Claire N. (2024). Identifying disease-modifying potential in myelofibrosis clinical trials. Blood Journal, 144 (16), 1679-1688. doi: 10.1182/blood.2024024220 |
|
2024 Journal Article Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND StudyYeung, David T., Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes S.M., Shortt, Jake, Chee, Lynette, Viiala, Nicholas, Cunningham, Ilona, Ross, David M., D'Souza, Alwyn Bernard, Wright, Matthew, Harrup, Rosemary Anne, Forsyth, Cecily Jane, Filshie, Robin, Lane, Steven W., Browett, Peter J., Grove, Carolyn S., Grigg, Andrew A. and Hughes, Timothy P. (2024). Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND Study. Blood Journal, 144 (19), 1993-2001. doi: 10.1182/blood.2024024657 |
|
2024 Conference Publication 3035 – INTERFERON ALPHA THERAPY ATTENUATES LEUKAEMIC TRANSFORMATION IN JAK2V617F-DRIVEN MPN WITH TRP53-LOSSBywater, Megan, Zhang, Ranran, Grabek, Julian, Halder, Rohit, Janardhanan, Yashaswini, Cooper, Leanne, Cooper, Emily, Ross, David, Straube, Jasmin and Lane, Steven (2024). 3035 – INTERFERON ALPHA THERAPY ATTENUATES LEUKAEMIC TRANSFORMATION IN JAK2V617F-DRIVEN MPN WITH TRP53-LOSS. EXPHEM 2024, Philadelphia, PA, United States: Elsevier BV. doi: 10.1016/j.exphem.2024.104357 |
|
2024 Conference Publication Performance of eight different severity scores to predict critical care admission in paediatric inpatients treated for sepsis: a retrospective cohort studyDeef, Minnah, Bracken, Abbey, Lane, Steven, Gittings, Robert, Curran, Rachel, Foreman, Rachael, Gawne, Andrew, Carter, Bernie, Saron, Holly, Eyton-Chong, Chin-Kien, Mehta, Fulya, Siner, Sarah, Lambert, Caroline, Sefton, Gerri and Carrol, Enitan D (2024). Performance of eight different severity scores to predict critical care admission in paediatric inpatients treated for sepsis: a retrospective cohort study. Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Birmingham, United Kingdom, 25 - 27 March 2024. London, United Kingdom: BMJ Group. doi: 10.1136/archdischild-2024-rcpch.491 |
|
2024 Journal Article Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortalityScho, Jeremy, Abrams, Simon T., Jenkins, Rosalind, Lane, Steven, Wang, Guozheng and Toh, Cheng-Hock (2024). Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality. Blood Advances, 8 (10), 2499-2508. doi: 10.1182/bloodadvances.2023012473 |
|
2024 Journal Article Survival for the fittest: guadecitabine in rel/ref AMLSheehy, Joshua and Lane, Steven W. (2024). Survival for the fittest: guadecitabine in rel/ref AML. Blood Advances, 8 (8), 2018-2019. doi: 10.1182/bloodadvances.2024012569 |
|
2024 Journal Article Autophagy prevents graft failure during murine Graft versus Host DiseaseLineburg, Katie E., Leveque-El Mouttie, Lucie, Hunter, Christopher R., Le Texier, Laeitia, McGirr, Crystal, Teal, Bianca, Blazar, Bruce R., Lane, Steven W., Hill, Geoffrey R., Levesque, Jean-Pierre and MacDonald, Kelli P.A. (2024). Autophagy prevents graft failure during murine Graft versus Host Disease. Blood Advances, 8 (8), 2032-2043. doi: 10.1182/bloodadvances.2023010972 |
|
2024 Journal Article Low iodine nutrition knowledge in Chinese breastfeeding women despite adequate iodine statusLiu, Shuchang, Sharp, Andrew, Lane, Steven, Villanueva, Elmer V., Lu, Zhiliang and Ma, Zheng Feei (2024). Low iodine nutrition knowledge in Chinese breastfeeding women despite adequate iodine status. Nutrients, 16 (4) 491, 1-14. doi: 10.3390/nu16040491 |
|
2024 Journal Article Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesCampbell, Ashlea, Teh, Benjamin, Mulligan, Stephen, Ross, David M., Weinkove, Robert, Gilroy, Nicole, Gangatharan, Shane, Prince, Henry Miles, Szer, Jeff, Trotman, Judith, Lane, Steven, Dickinson, Michael, Quach, Hang, Enjeti, Anoop K., Ku, Matthew, Gregory, Gareth, Hapgood, Gregory, Ho, Phoebe Joy, Cochrane, Tara, Cheah, Chan, Greenwood, Matthew, Latimer, Maya, Berkahn, Leanne, Wight, Joel, Armytage, Tasman, Diamond, Peter, Tam, Constantine S. and Hamad, Nada (2024). Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies. Internal Medicine Journal, 54 (2), 328-336. doi: 10.1111/imj.16303 |
|
2024 Journal Article A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB studyQurashi, Inti, Chaudhry, Imran B., Khoso, Ameer B., Husain, Muhammad Omair, Hafeez, Danish, Kiran, Tayyeba, Lane, Steven, Naqvi, Haider A., Minhas, Fareed A., Nizami, Asad Tamizuddin, Razzaque, Bushra, Bokhari, Sumira Qambar, Yung, Alison R., Deakin, Bill and Husain, Nusrat (2024). A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study. Brain Behavior and Immunity, 115, 609-616. doi: 10.1016/j.bbi.2023.10.025 |
|
2024 Journal Article Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemiaBruedigam, Claudia, Porter, Amy H., Song, Axia, Vroeg in de Wei, Gerjanne, Stoll, Thomas, Straube, Jasmin, Cooper, Leanne, Cheng, Guidan, Kahl, Vivian F. S., Sobinoff, Alexander P., Ling, Victoria Y., Jebaraj, Billy Michael Chelliah, Janardhanan, Yashaswini, Haldar, Rohit, Bray, Laura J., Bullinger, Lars, Heidel, Florian H., Kennedy, Glen A., Hill, Michelle M., Pickett, Hilda A., Abdel-Wahab, Omar, Hartel, Gunter and Lane, Steven W. (2024). Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nature Cancer, 5 (1), 47-65. doi: 10.1038/s43018-023-00653-5 |
